**About the Editors**

#### **Paolo Magni**

Paolo Magni, MD-PhD, is professor at the Universita degli Studi di Milano (Milan, Italy) and ` collaborates with IRCCS MultiMedica hospital (Milan, Italy). He is interested in experimental and clinical research of cardio-metabolic diseases, including the identification and validation of novel biomarkers using omics approaches and the experimental and clinical assessment of the safety and efficacy of innovative nutraceutical products. He is currently the coordinator of two European projects on the assessment of atherosclerotic cardiovascular disease risk using multiomic technologies and artificial intelligence/machine learning strategies.

#### **Andrea Baragetti**

Andrea Baragetti, PhD, is professor at the Universita degli Studi di Milano (Milan, Italy) and ` collaborates with IRCCS MultiMedica hospital (Milan, Italy). He is interested in experimental and clinical research of lipid disorders in the context of cardio-metabolic diseases, including the validation of biomarkers using omics approaches and their relationship with nutritional features and nutraceutical approaches. He is currently the holder of research projects aimed at assessing specific aspects of the pathophysiology of cardiometabolic diseases.

#### **Andrea Poli**

Andrea Poli, MD, is President of the Nutrition Foundation of Italy (NFI). In this capacity, he promotes scientific studies in the fields of nutrition and nutraceutical products, with specific interests regarding lipoprotein disorders and atherosclerosis, population interventions for atherosclerosis prevention, and the study of the distribution of risk factors in the Italian population.
